Biovie (BIVI) Notes Payables (2023 - 2024)
Biovie (BIVI) posted Notes Payables of $3.3 million for Q3 2024, down 41.76% sequentially from $5.7 million in Q2 2024, and down 64.45% YoY from $9.3 million in Q4 2023.
Biovie (BIVI) Notes Payables (2023 - 2024) Analysis & Trends
Biovie has reported Notes Payables for 2 years, with the latest figure at $3.3 million in Q3 2024.
- Quarterly Notes Payables fell 64.45% year-over-year to $3.3 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $3.3 million (down 64.45% YoY) and the FY2024 annual result came in at $5.7 million, down 37.38% from the prior year.
- Notes Payables retreated to $3.3 million in Q3 2024 per BIVI's latest filing, from $5.7 million in the prior quarter.
- Over five years, Notes Payables peaked at $10.2 million in Q4 2023 and troughed at $3.3 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Biovie | 14.17 Mn | 14.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 3.32 Mn |
| Jun 30, 2024 | 5.70 Mn |
| Mar 31, 2024 | 7.99 Mn |
| Dec 31, 2023 | 10.20 Mn |
| Sep 30, 2023 | 9.34 Mn |
| Jun 30, 2023 | 9.11 Mn |
| Mar 31, 2023 | 6.39 Mn |